High-dose intermittent sunitinib therapy retains the crown

Abstract

The approved first-line therapy for advanced-stage renal cell carcinoma (RCC) is high-dose (50 mg per day) intermittent dosing of sunitinib (4 weeks on and 2 weeks off treatment, called schedule 4/2). Although a low-dose (37.5 mg per day) continuous daily dosing (CDD) of sunitinib has been recommended as an alternative schedule, a new study now suggests that the low-dose CDD schedule has no benefit in efficacy and safety over the approved high-dose schedule.